MAPT and Alzheimer disease: Studies have found that SCFAs improved cognition by reducing Aβ and tau pathology, regulating microglial functions, alleviating neuroinflammation, and increasing the expression of learning associated genes via histone deacetylase inhibition in rodent models in AD.10, 11